Abstract:AIM:To investigate the efficacy and safety of capecitabine and oxaliplatin (CapeOx) for extrahepatic metastasis after local treatment of hepatocellular carcinoma (HCC).METHODS:Thirty-two patients with extrahepatic metastasis of HCC after local treatment were prospectively enrolled. The CapeOx regimen consisted of capecitabine 1000 mg/m(2) taken orally twice daily on days 1-14, and oxaliplatin was administered at a total dose of 100 mg/m(2) on day 1. The treatment was repeated every 3 wk until disease progression or unaccetablle toxicity. Efficacy and safety were assessable for all enrolled patients. The primary objective of this study was to assess the overall response rate. The secondary objectives were to evaluate the overall survival (OS), the time to tumor progression (TTP) and the toxicity profile of the combined strategy. TTP and OS were assessed by the Kaplan-Meier method and differences between the curves were analyzed using the log-rank test. The statistical software SPSS version 15.0 for Windows (SPSS Inc., Chicago, IL, United States) was used for statistical analysis. All P values were 2-tailed, with statistical significance defined by P ≤ 0.05.RESULTS:Thirty-two patients were assessable for efficacy and toxicity. The median follow-up duration was 15 mo (range, 12-20 mo). At the cut-off date of March 31, 2012, 27 patients died due to tumor progression and one patient died of myocardial infarction. Four patients were still alive (three patients with disease progression). OR was 21.9% (n = 7), the stabilization rate was 40.6% (n = 13), and the disease control rate was 62.5%. The responses lasted from 4 to 19 mo (median, 6 mo). Median TTP was 4.2 mo (95%CI: 2.5-7.4), and the median OS time was 9.2 mo (95%CI: 6.5-17.8). The 1-year survival rate was 43.6% (95%CI: 29.0-66.0). In a multivariate analysis, OS was significantly longer in patients with a Child-Pugh class A compared with class B patients (P = 0.014), with a median OS of 10.1 mo vs 5.4 mo, and there were trends towards longer OS (P = 0.065) in patients without portal vein tumor thrombosis. There were no significant effects of age, gender, performance status, cirrhosis, metastatic sites, and level of alpha fetoprotein (AFP) or hepatitis B virus-DNA on OS. Among the 22 patients with elevated AFP levels at baseline (≥ 400 ng/mL), the level fell by more than 50% during treatment in 6 patients (27.3%). The most frequent treatment-related grade 3 to 4 toxicities included leucopenia/neutropenia, transient elevation of aminotransferases, hand-foot syndrome and fatigue.CONCLUSION:CapeOx showed modest anti-tumor activity in metastatic HCC. However, the manageable toxicity profile and the encouraging disease control rate deserve further study for these patients.

Intra-arterial Infusion with Oxaliplatin for Cases with Previously Treated Liver Metastasis

Efficacy of the radiotherapy combined with oxaliplatin and capecitabine in the treatment of local advanced rectal cancer

Efficacy of Oxaliplatin Combined with Pirarubicin and 5-Fluorouracil for Advanced Hepatocellular Carcinoma

Clinical research on oxaliplatin or irinotecan plus capecitabine for colorectal liver metastasis treatment

Hepatic Arterial Infusion Oxaliplatin Plus Oral S-1 Chemotherapy in Gastric Cancer with Unresectable Liver Metastases: A Case Series and Literature Review

Short-term efficacy of oxaliplatin as interventional therapy for liver cancer, and its effect on serum CD163 and AFU

WEEKLY DOSE OXALIPLATIN IN THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC CANCER

Efficacy of hepatic arterial infusion chemotherapy in patients with primary liver cancer with portal vein tumor thrombosis: a comparative analysis of different perfusion chemotherapeutic regimens

Phase II Study of Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Perihilar Cholangiocarcinoma.

Oxaliplatin-induced peripheral neuropathy with hepatic arterial versus intravenous infusion in metastatic colorectal cancer

Efficacy of Capecitabine and Oxaliplatin Regimen for Extrahepatic Metastasis of Hepatocellular Carcinoma Following Local Treatments.

Clinical Study of Hepatic Artery Infusion Chemotherapy for Prevention of Hepatic Metastasis in Patients with Colorectal Cancer Stage Ⅲ

Treatment of Advanced and Metastatic Colorectal Cancer with Combined Chemotherapy Based on Oxaliplatin, Irinotecan and Fluorouracil

Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer

Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases

Preparation and Experimental Application of Oxaliplatin-loaded Alumin Nanoparticles for Intraperitoneal Chemotherapy in Colorectal Cancer

Hepatic Artery Infusion and Systemic XELOX Chemotherapy for Gastric and Colorectal Cancer with Liver Metastasis:Analysis of Curative Effect and Safety

Intra-Arterial Infusion Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Preliminary Experience on the Safety, Efficacy, and Clinical Outcomes

The Effects of Oxaliplatin on the Invasion and Metastatic Potential of Orthotopic Hepatocellular Carcinoma Nude Mice Model Established with Fluorescent HepG2 Cells

A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases

Interventional treatment for progressive hepatic metastases from gastric cancer after chemotherapy: a retrospective analysis of 72 cases